Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence
10.1007/bf02246489
Crossref journal-article
Springer Science and Business Media LLC
Psychopharmacology (297)
Bibliography

LeDuc, P. A., & Mittleman, G. (1995). Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology, 121(4), 407–427.

Authors 2
  1. P. A. LeDuc (first)
  2. G. Mittleman (additional)
References 127 Referenced 65
  1. American Medical Association (1991) Drug Evaluations Annual. AMA, Milwaukee, pp 238–267 / Drug Evaluations Annual by American Medical Association (1991)
  2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. American Psychiatric Association, Washington, D.C. / Diagnostic and Statistical Manual of Mental Disorders by American Psychiatric Association (1987)
  3. Andreasen NC (1990) Positive and negative symptoms: historical and conceptual aspects. Mod Probl Pharmacopsychiatry 24:1–42 (10.1159/000418010) / Mod Probl Pharmacopsychiatry by NC Andreasen (1990)
  4. Angrist BM, Gershon S (1970) The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biol Psychiatry 2:95–107 / Biol Psychiatry by BM Angrist (1970)
  5. Arndt S, Tyrrell G, Flaum M, Andreasen N (1992) Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol Med 22:379–388 (10.1017/S0033291700030324) / Psychol Med by S Arndt (1992)
  6. Bagshaw RJ, Shaw LM, August T, Young ML, Conahan TJ (1993) Unregulated self-medication in an ambulatory surgery population. Aviat Space Environ Med 64:324–326 / Aviat Space Environ Med by RJ Bagshaw (1993)
  7. Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In Goodman Gillman A, Rall T, Nies A, Taylor P (eds) Goodman and Gillman's the pharmacological basis of therapeutics. Pergamon Press, New York, pp 383–435 / Goodman and Gillman's the pharmacological basis of therapeutics by RJ Baldessarini (1990)
  8. Barbee JG, Clark PD, Crapanzano MS, Heintz GC, Kehoe CE (1989) Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service. J Nerv Ment 177:400–407 (10.1097/00005053-198907000-00003) / J Nerv Ment by JG Barbee (1989)
  9. Bell DS (1965) Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111:701–707 (10.1192/bjp.111.477.701) / Br J Psychiatry by DS Bell (1965)
  10. Bergman HC, Harris M (1985) Substance abuse among young adult chronic patients. Psychosocial Rehabil J 9:49–54 (10.1037/h0099162) / Psychosocial Rehabil J by HC Bergman (1985)
  11. Bhattacharyya A, Aulakh C, Pradhan S, Ghosh P, Pradhan S (1979) Modification of behavioral and neurochemical effects of cocaine by haloperidol. Arch In Pharmacology 238:71–80 / Arch In Pharmacology by A Bhattacharyya (1979)
  12. Brady K, Anton R, Ballenger JC, Lydiard RB, Adinoff B, Selander J (1990) Cocaine abuse among schizophrenic patients. Am J Psychiatry 147:1164–1167 (10.1176/ajp.147.1.115) / Am J Psychiatry by K Brady (1990)
  13. Brady K, Casto S, Lydiard R, Malcolm R, Arana G (1991) Substance abuse in an inpatient psychiatric sample. Am J Drug Alcohol Abuse 17:389–397 (10.3109/00952999109001598) / Am J Drug Alcohol Abuse by K Brady (1991)
  14. Breakey WR, Goodell H (1972) Thought disorder in mania and schizophrenia evaluated by Bannister's grid test for schizophrenic thought disorder. Br J Psychiatry 120:391–395 (10.1192/bjp.120.557.391) / Br J Psychiatry by WR Breakey (1972)
  15. Breakey WR, Goodell H, Lorenz PC, McHugh PR (1974) Hallucinogenic drugs as precipitants of schizophrenia. Psychol Med 4:255–261 (10.1017/S0033291700042938) / Psychol Med by WR Breakey (1974)
  16. Brockington I (1986) Diagnosis of schizophrenia and schizoaffective psychoses. In Bradley PB, Hirsch SR (eds) The psychopharmacology and treatment of schizophrenia. Oxford University Press, Oxford, pp 166–199 / The psychopharmacology and treatment of schizophrenia by I Brockington (1986)
  17. Bunt G, Galanter M, Lifshutz H, Castaneda R (1990) Cocaine/”Crack” dependence among psychiatric inpatients Am J Psychiatry 147:1542–1546 (10.1176/ajp.147.11.1542) / Am J Psychiatry by G Bunt (1990)
  18. Burke WM, Ravi NV, Dhopesh V, Vandigrift B, Maany I (1990) Prolonged presence of metabolite in urine after compulsive cocaine use J Clin Psychiatry 51:145–148 / J Clin Psychiatry by WM Burke (1990)
  19. Carlsson A (1978) Mechanism of action of neuroleptic drugs. In Lipton MA, DiMascio A, Killian KF (eds) Psychopharmacology: a generation in progress. Raven Press, New York, pp 1057–1070 / Psychopharmacology: a generation in progress by A Carlsson (1978)
  20. Christie KA, Burke JD, Reiger DA, Rae DS, Boyd JH, Locke BZ (1988) Epidemiological evidence for early onset of mental disorders and high risk of drug abuse in young adults. Am J Psychiatry 145:971–975 (10.1176/ajp.145.8.971) / Am J Psychiatry by KA Christie (1988)
  21. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM. Franco S (1991) Substance abuse and schizophrenia: Effects on symptoms but not on neurocognitive function. J Clin Psychiatry 52:26–30 / J Clin Psychiatry by JM Cleghorn (1991)
  22. Connell PH (1958) Amphetamine Psychosis. Oxford University Press, New York / Amphetamine Psychosis by PH Connell (1958)
  23. Creese I, Iversen SD (1975) The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 83:419–436 (10.1016/0006-8993(75)90834-3) / Brain Res by I Creese (1975)
  24. Csernansky JG, Bellows EP, Barnes DE, Lombrozo L (1990) Sensitization to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing. Psychopharmocology 101:19–524 (10.1007/BF02244231) / Psychopharmocology by JG Csernansky (1990)
  25. Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment 180:589–592 (10.1097/00005053-199209000-00008) / J Nerv Ment by BJ Cuffel (1992)
  26. Davidson ES, Finch JF, Schenk, S (1993) Variability in subjective responses to cocaine: Initial experiences of college students. Addict Behav 18:445–453 (10.1016/0306-4603(93)90062-E) / Addict Behav by ES Davidson (1993)
  27. Davis JM (1975) Overview maintenance therapy in psychiatry. I: schizophrenia. Am J Psychiatry 132:1237–1245 (10.1176/ajp.132.12.1237) / Am J Psychiatry by JM Davis (1975)
  28. Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M (1993) Dose response of prophylactic antipsychotics. J Clin Psychiatry (Suppl) 54:24–30 / J Clin Psychiatry by JM Davis (1993)
  29. De Wit H, Wise RA (1977) Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine and phenoxbenzamine. Can J Psychol 31:195–203 (10.1037/h0081662) / Can J Psychol by H Wit De (1977)
  30. De Wit H, Uhlenhuth EH, Johanson CE (1986) Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 16:341–360 (10.1016/0376-8716(86)90068-2) / Drug Alcohol Depend by H Wit De (1986)
  31. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Notl Acad Sci USA 85:5274–5278 (10.1073/pnas.85.14.5274) / Proc Notl Acad Sci USA by G Chiara Di (1988)
  32. Dixon L, Haas G, Weiden P, Sweeney J (1990) Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 16:69–79 (10.1093/schbul/16.1.69) / Schizophr Bull by L Dixon (1990)
  33. Dixon L, Haas G, Weiden P, Sweeney J, Frances AJ (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148:224–230 (10.1176/ajp.148.2.224) / Am J Psychiatry by L Dixon (1991)
  34. Elangovan N, Berman S, Meinzer A, Gianelli P, Miller H, Longmore W (1993) Substance abuse among patients presenting to an inner-city psychiatric emergency room. Hosp Commun Psychiatry 44:782–784 / Hosp Commun Psychiatry by N Elangovan (1993)
  35. Ellinwood EH, Kilbey MM (1977) Chronic stimulant intoxication models of psychosis. In: Hanin I, Usdin E (eds) Animal models in psychiatry and neurology. Pergamon Press, New York, pp 61–74 / Animal models in psychiatry and neurology by EH Ellinwood (1977)
  36. Estroff TW, Gold MS (1985) Medical and psychiatric complications of cocaine abuse with possible points of pharmacological treatment. Adv Alcohol Subst Abuse 5:61–76 (10.1300/J251v05n01_05) / Adv Alcohol Subst Abuse by TW Estroff (1985)
  37. Fenton WS, McGlashan TH (1991) Natural history of schizophrenia subtypes II. Positive and negative symptoms and longterm course. Arch Gen Psychiatry 48:978–986 (10.1001/archpsyc.1991.01810350018003) / Arch Gen Psychiatry by WS Fenton (1991)
  38. Ferguson GA, Takane Y (1989) Statistical analysis in psychology and education. McGraw-Hill, New York / Statistical analysis in psychology and education by GA Ferguson (1989)
  39. Fischman MW (1989) Relationship between self-reported drug effects and their reinforcing effects: Studies with stimulant drugs. NIDA Res Monogr 92:211–230 / NIDA Res Monogr by MW Fischman (1989)
  40. Fishman MW, Schuster CR, Krasnegor NA (1977) Physiological and behavioral effects of intravenous cocaine in man. In: Ellinwood EH, Kilbey MM (eds) Cocaine and other stimulants (advances in behavioral biology, vol 21). Plenum Press, New York, pp 647–664 (10.1007/978-1-4684-3087-5_32) / Cocaine and other stimulants (advances in behavioral biology, vol 21) by MW Fishman (1977)
  41. Foltz, RL, Fentiman, AF, Foltz, RB (1980) GC/MS assays for abused drugs in body fluids. NIDA Res Monogr 32
  42. Galanter M, Castaneda R, Ferman J (1988) Substance abuse among general psychiatric patients: place of presentation, diagnosis and treatment. Am J Drug Alcohol Abuse 142:211–235 (10.3109/00952999809001548) / Am J Drug Alcohol Abuse by M Galanter (1988)
  43. Galanter M, Egelko S, De Leon G, Rohrs C, Franco H (1992) Crack/Cocaine abusers in the general hospital: assessment and initiation of care. Am J Psychiatry 149:810–815 (10.1176/ajp.149.6.810) / Am J Psychiatry by M Galanter (1992)
  44. Gawin FH (1986) Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology 90:142–143 (10.1007/BF00172886) / Psychopharmacology by FH Gawin (1986)
  45. Gawin FH, Kleber HD (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 43:107–113 (10.1001/archpsyc.1986.01800020013003) / Arch Gen Psychiatry by FH Gawin (1986)
  46. Goeders NE, Smith JE (1983) Cortical dopaminergic involvement in cocaine reinforcement. Science 221:773–774 (10.1126/science.6879176) / Science by NE Goeders (1983)
  47. Gold MS, Bowers MB (1978) Neurobiological vulnerability to lowdose amphetamine psychosis. Am J Psychiatry 135:1546–1548 (10.1176/ajp.135.12.1546) / Am J Psychiatry by MS Gold (1978)
  48. Gottesman I (1991) Schizophrenia genesis: the origins of madness. W.H. Freeman and Company, New York / Schizophrenia genesis: the origins of madness by I Gottesman (1991)
  49. Griffith JD, Cavanaugh J, Held J, Oates JA (1972) Dextroamphetamine: evaluation of psychomimmetic properties in man. Arch Gen Psychiatry 26:97–100 (10.1001/archpsyc.1972.01750200001001) / Arch Gen Psychiatry by JD Griffith (1972)
  50. Groves PN, Rebec GV (1976) Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs. Ann R Psych 27:91–127 (10.1146/annurev.ps.27.020176.000515) / Ann R Psych by PN Groves (1976)
  51. Hall RC, Popkin MK, Stickney SK, Gardner ER (1978) Covert outpatient drug abuse: incidence and therapist recognition. J Nerv Ment 166:343–348 (10.1097/00005053-197805000-00005) / J Nerv Ment by RC Hall (1978)
  52. Hansell N, Willis GL (1977) Outpatient treatment of schizophrenia. Am J Psychiatry 134:1082–1086 (10.1176/ajp.134.11.1321-a) / Am J Psychiatry by N Hansell (1977)
  53. Hansen HJ, Caudill SP, Boone J (1985) Crisis in drug testing: Results of a CDC blind study. JAMA 253:2382–2387 (10.1001/jama.1985.03350400066023) / JAMA by HJ Hansen (1985)
  54. Harrell AV (1985) Validation of self-report:the research record. NIDA Res Monogr 57:12–21 / NIDA Res Monogr by AV Harrell (1985)
  55. Hawks RL (1986) Analytical methodology. NIDA Res Monogr 73:30–42 / NIDA Res Monogr by RL Hawks (1986)
  56. Hegarty AM, Lipton RB, Merriam AE, Freeman K (1991) Cocaine as a risk factor for acute dystonic reactions. Neurology 41:1670–1672 (10.1212/WNL.41.10.1670) / Neurology by AM Hegarty (1991)
  57. Howell LL, Byrd LD (1992) Enhanced sensitivity to the behavioral effects of cocaine after chronic administrtaion of D2-selective sopamine antagonists in the squirrel monkey. J Pharmacol Exp Ther 262:907–915 / J Pharmacol Exp Ther by LL Howell (1992)
  58. Janowsky DS, Davis JM (1976) Methylphenidate, dextroamphetamine, and levamphetamine: effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304–308 (10.1001/archpsyc.1976.01770030024003) / Arch Gen Psychiatry by DS Janowsky (1976)
  59. Janowsky DS, El-Yousef MK, Davis JM, Sekerke J (1973) Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 28:185–191 (10.1001/archpsyc.1973.01750320023004) / Arch Gen Psychiatry by DS Janowsky (1973)
  60. Johnston LD, O'Malley PM, Bachman JG (1993) National survey results on drug use from the monitoring the future study, 1975–1992, volume II. National Institute on Drug Abuse, Rockville, MD, NIH Publication No. 93-3598 / National survey results on drug use from the monitoring the future study, 1975–1992, volume II / NIH Publication by LD Johnston (1993)
  61. Johnston LD, O'Malley PM, Bachman JG (1994) National survey results on drug use from the monitoring the future study, 1975–1993, volume II. National Institute on Drug Abuse, Rockville, MD, NIH Publication No. 94-3810 / National survey results on drug use from the monitoring the future study, 1975–1993, volume II / NIH Publication by LD Johnston (1994)
  62. Katz JL (1989) Drugs as reinforcers: pharmacological and behavioral factors. In: Liebman JM, Cooper, SJ (eds) The neuropharmacological basis of reward. Oxford University Press, Oxford, pp 164–213 / The neuropharmacological basis of reward by JL Katz (1989)
  63. Kety S (1981) Neurochemical and genetic basis of psychopathology: current status. Behav Genet 12:93–100 (10.1007/BF01065742) / Behav Genet by S Kety (1981)
  64. Kety S (1983) Mental illness in the biological and adoptive relatives of schizophrenic adoptees: findings relevant to genetic and environmental factors in etiology. Am J Psychiatry 140:720–727 (10.1176/ajp.140.7.964) / Am J Psychiatry by S Kety (1983)
  65. Khantzian EJ (1985) The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142:1259–1264 (10.1176/ajp.142.11.1259) / Am J Psychiatry by EJ Khantzian (1985)
  66. Kivlahan DR, Heiman JR, Wright RC, Mundt JW, Shupe JA (1991) Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse. Hosp Commun Psychiatry 42:609–614 / Hosp Commun Psychiatry by DR Kivlahan (1991)
  67. Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science 242:715–723 (10.1126/science.2903550) / Science by GF Koob (1988)
  68. Kuczenski R (1983) Biochemical Actions of Amphetamine and Other Stimulants. In Creese I (ed) Stimulants: neurochemical, behavioral, and clinical perspectives. Raven Press, New York, pp 31–61 / Stimulants: neurochemical, behavioral, and clinical perspectives by R Kuczenski (1983)
  69. Kuczenski R, Segal DS, Aizenstein ML (1991) Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 11:2703–2712 (10.1523/JNEUROSCI.11-09-02703.1991) / J Neurosci by R Kuczenski (1991)
  70. Lawson WB (1994) Movement disorders in schizophrenic substance abusers. Biol Psychiatry 35:731 (10.1016/0006-3223(94)91076-6) / Biol Psychiatry by WB Lawson (1994)
  71. LeDuc PA, Mittleman G (1993) Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology 110:427–436 (10.1007/BF02244649) / Psychopharmacology by PA LeDuc (1993)
  72. LeDuc PA, Mittleman G (1995) The effects of chronic haloperidol and intermittent cocaine administration on behavior elicited by apomorphine. Exp Clin Psychopharmacol 3:15–25 (10.1037/1064-1297.3.1.15) / Exp Clin Psychopharmacol by PA LeDuc (1995)
  73. Lett BT (1989) Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine and cocaine. Psychophar 98:357–362 (10.1007/BF00451687) / Psychophar by BT Lett (1989)
  74. Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychophar 91:415–433 (10.1007/BF00216006) / Psychophar by JA Lieberman (1987)
  75. Louilot A, Buda M, Gonon F, Simon H, Le Moal M, Pujol JF (1985) Effect of haloperidol and sulpiride on dopamine metabolism in nucleus accumbens and olfactory tubercle: a study by in vivo voltammetry. Neuroscience 14:775–82 (10.1016/0306-4522(85)90142-3) / Neuroscience by A Louilot (1985)
  76. Lysaker P, Bell M, Beam-Goulet J, Milstein R (1994) Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment 182:109–112 (10.1097/00005053-199402000-00008) / J Nerv Ment by P Lysaker (1994)
  77. McLellan AT, Druley KA (1977) Non-random relation between drugs of abuse and psychiatric diagnosis. J Psychiatr Res 13:179–184 (10.1016/0022-3956(77)90007-3) / J Psychiatr Res by AT McLellan (1977)
  78. McNagny SE, Parker RM (1992) High prevalence of recent cocaine use and the unreliability of patient self-report in an inner city walk-in clinic. JAMA 267:1106–1108 (10.1001/jama.1992.03480080076030) / JAMA by SE McNagny (1992)
  79. Mesulam MM (1986) Cocaine and Tourette's syndrome. N Eng J Med 315:398 / N Eng J Med by MM Mesulam (1986)
  80. Mieczkowski T (1990) The accuracy of self-reported drug use: an evaluation and analysis of new data. In: Weisheit R (ed) Drugs, crime and the criminal justice system. Anderson Publishing Co, Cincinnati, pp 275–302 / Drugs, crime and the criminal justice system by T Mieczkowski (1990)
  81. Mieczkowski T, Newel R (1993) An evaluation of patterns of racial bias in hair assays for cocaine: black and white arrestees compared. Forens Sci Int 63:85–98 (10.1016/0379-0738(93)90262-9) / Forens Sci Int by T Mieczkowski (1993)
  82. Mieczkowski T, Barzelay D, Gropper B, Wish E (1991) Concordance of three measures of cocaine use in an arrestee population: hair, urine, and self-report. J Psychoact Drugs 23:241–249 (10.1080/02791072.1991.10471585) / J Psychoact Drugs by T Mieczkowski (1991)
  83. Miller FT, Tanenbaum JH (1989) Drug abuse in schizophrenia. Hosp Commun Psychiatry 40:847–849 / Hosp Commun Psychiatry by FT Miller (1989)
  84. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Morrison RL, Yadalam KG (1990) Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull 16:31–56 (10.1093/schbul/16.1.31) / Schizophr Bull by KT Mueser (1990)
  85. Mueser KT, Yarnold PR, Bellack AS (1992) Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr Scand, 85:48–55 (10.1111/j.1600-0447.1992.tb01441.x) / Acta Psychiatr Scand by KT Mueser (1992)
  86. National Institute on Drug Abuse (1991) National household survey on drug abuse: main findings 1990. National Institute on Drug Abuse, Rockville, md. DHHS Publication No. (ADM) 91-1788 / National household survey on drug abuse: main findings 1990 / DHHS Publication by National Institute on Drug Abuse (1991)
  87. O'Brien CP, Ehrman RN, Ternes JN (1986) Classical conditioning in human opioid dependence. In: Goldberg SR, Stolerman IP (eds) Behavioral analysis of drug dependence. Academic Press, London, pp 329–356 / Behavioral analysis of drug dependence by CP O'Brien (1986)
  88. Osterloh J (1993) Testing for drugs of abuse: Pharmacokinetic considerations for cocaine in urine. Clin Pharmacokinet 24:355–361 (10.2165/00003088-199324050-00001) / Clin Pharmacokinet by J Osterloh (1993)
  89. Pettit HO, Justice JB (1989) Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol Biochem Behav 34:899–904 (10.1016/0091-3057(89)90291-8) / Pharmacol Biochem Behav by HO Pettit (1989)
  90. Piazza PV, Deminiere JM, Le Moal M, Simon H (1989) Factors that predict individual vulnerability to amphetamine self-administration. Science 245:1511–1513 (10.1126/science.2781295) / Science by PV Piazza (1989)
  91. Picker D (1988) Perspectives on a time-dependent model of neuroleptic action. Schizophr Bull 14:255–268 (10.1093/schbul/14.2.255) / Schizophr Bull by D Picker (1988)
  92. Post RM (1981) Central stimulants: clinical and experimental evidence on tolerance and sensitization. In: Israel Y, Glaser FB, Kalant H, Popham RE, Schmidt W, Smart RG (eds) Research advances in alcohol and drug problems, vol. 6. Plenum Press, New York, pp 1–65 (10.1007/978-1-4615-7740-9_1) / Research advances in alcohol and drug problems, vol. 6 by RM Post (1981)
  93. Pulvirenti L, Swerdlow NR, Hubner CB, Koob GF (1991) The role of limbic-accumbens-pallidal circuitry in the activating and reinforcing properties of psychostimulant drugs. In: Willner P, Scheel-Kruger J (eds) The mesolimbic dopamine system: from motivation to action. Wiley, New York, pp 131–140 / The mesolimbic dopamine system: from motivation to action by L Pulvirenti (1991)
  94. Randrup A, Munkvad I, Usden P (1963) Adrenergic mechanisms and amphetamine induced abnormal behavior. Acta Pharmacol Toxicol 20:145–157 (10.1111/j.1600-0773.1963.tb01731.x) / Acta Pharmacol Toxicol by A Randrup (1963)
  95. Rastogi SK, Rastogi RB, Singhal RL, Lapierre YD (1983) Behavioural and biochemical alterations following haloperidol treatment withdrawal: the animal model reexamined. Prog Neuropsychopharmacol 7:153–164 (10.1016/0278-5846(83)90102-1) / Prog Neuropsychopharmacol by SK Rastogi (1983)
  96. Resnick RB, Kestenbaum RS, Schwartz LK (1977) Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 195:696–698 (10.1126/science.841307) / Science by RB Resnick (1977)
  97. Richard ML, Liskow BI, Perry PJ (1985) Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 46:79–83 / J Clin Psychiatry by ML Richard (1985)
  98. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223 (10.1126/science.2820058) / Science by MC Ritz (1987)
  99. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaulation of animal models of amphetamine psychosis. Brain Res Rev 11:157–198 (10.1016/0165-0173(86)90002-0) / Brain Res Rev by TE Robinson (1986)
  100. Robinson TE, Berridge KC (1993) The neural basis of drug craving: and incentive-sensitization theory of addiction. Brain Res Rev 18:247–291 (10.1016/0165-0173(93)90013-P) / Brain Res Rev by TE Robinson (1993)
  101. Rockwell DA, Ostwald P (1968) Amphetamine use and abuse in psychiatric patients. Arch Gen Psychiatry 18:612–616 (10.1001/archpsyc.1968.01740050100017) / Arch Gen Psychiatry by DA Rockwell (1968)
  102. Rosenthal RN, Hellerstein DJ, Miner CR (1994) Positive and negative syndrome typology in schizophrenic patients with psychoactive substance use disorders. Comp Psychiatry 35:91–98 (10.1016/0010-440X(94)90052-J) / Comp Psychiatry by RN Rosenthal (1994)
  103. Schneier FR, Siris SG (1987) A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment 175:641–652 (10.1097/00005053-198711000-00001) / J Nerv Ment by FR Schneier (1987)
  104. Schnoll SH, Daghestani AN, Hansen TR (1984) Cocaine dependence. Resident Staff Physician 30:24–31 / Resident Staff Physician by SH Schnoll (1984)
  105. Segal DS, Mandell AJ (1974) Long-term administration of Damphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem B 2:249–255 (10.1016/0091-3057(74)90060-4) / Pharmacol Biochem B by DS Segal (1974)
  106. Seibyl JP, Satel SL, Anthony D, Southwick SM, Krystal JH, Charney DS (1993) Effects of cocaine on hospital course in schizophrenia. J Nerv Ment 181:31–37 (10.1097/00005053-199301000-00006) / J Nerv Ment by JP Seibyl (1993)
  107. Sevy S, Kay SR, Opler LA, Praag HM (1990) Significance of cocaine history in schizophrenia. J Nerv Ment 178:642–648 (10.1097/00005053-199010000-00005) / J Nerv Ment by S Sevy (1990)
  108. Shaner A, Khalsa ME, Roberts L, Wilkins J, Anglin D, Hsieh SC (1993) Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 150:758–762 (10.1176/ajp.150.5.758) / Am J Psychiatry by A Shaner (1993)
  109. Siris SG, Kane JM, Frechen K, Sellew AP, Mandeli J, Fasano-Dube B (1988) Histories of substance abuse in patients with postpsychotic depressions. Compr Psychiatry 29:550–557 (10.1016/0010-440X(88)90074-0) / Compr Psychiatry by SG Siris (1988)
  110. Spitzer RL (1980) Introduction. In: American Psychiatric Association: diagnostic and statistical manual of mental disorders, 3rd Edn. APA, Washington D.C., pp 1–12 / American Psychiatric Association: diagnostic and statistical manual of mental disorders by RL Spitzer (1980)
  111. Stone AM, Greenstein RA, Gamble G, McLellan AT (1993) Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Hosp Commun Psychiatry 44:176–177 / Hosp Commun Psychiatry by AM Stone (1993)
  112. Swerdlow NR, Vaccarino FJ, Amalric M, Koob GF (1986) The neural substrate for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol Biochem Behav 25:233–248 (10.1016/0091-3057(86)90261-3) / Pharmacol Biochem Behav by NR Swerdlow (1986)
  113. Test MA, Wallisch LS, Allness DJ, Ripp K (1989) Substance use in young adults with schizophrenic disorders. Schizophr Bull 15:465–476 (10.1093/schbul/15.3.465) / Schizophr Bull by MA Test (1989)
  114. Weiss RD, Gawin FH (1988) Protracted elimination of cocaine metabolites in long-term high-dose abusers. Am J Med 85:879–880 (10.1016/S0002-9343(88)80042-1) / Am J Med by RD Weiss (1988)
  115. Weiss RD, Mirin SM, Michael JL, Sollogub AC (1986) Psychopathology in chronic cocaine abusers. Am J Drug Alcohol Abuse 12:17–29 (10.3109/00952998609083740) / Am J Drug Alcohol Abuse by RD Weiss (1986)
  116. White FJ, Wang RY (1983) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 32:983–993 (10.1016/0024-3205(83)90929-3) / Life Sci by FJ White (1983)
  117. Wilkins JN, Shaner AL, Patterson CM, Setoda, D, Gorelick D (1991) Discrepancies between patient report, clinical assessment, and urine analysis in psychiatric patients during inpatient admission. Psychopharmacol Bull 27:149–154 / Psychopharmacol Bull by JN Wilkins (1991)
  118. Wilmot CA, Szczepanik AM (1989) Effects of acute treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487:288–298 (10.1016/0006-8993(89)90833-0) / Brain Res by CA Wilmot (1989)
  119. Wise RA (1982) Neuroleptics and operant behavior: The anhedonia hypothesis. Behav Brain Sci 5:39–88 (10.1017/S0140525X00010372) / Behav Brain Sci by RA Wise (1982)
  120. Wise RA (1984) Neural mechanisms of the reinforcing action of cocaine. NIDA Res Monogr 50:5–33 / NIDA Res Monogr by RA Wise (1984)
  121. Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94:469–492 (10.1037/0033-295X.94.4.469) / Psychol Rev by RA Wise (1987)
  122. Witkin JM (1994) Pharmacotherapy of cocaine abuse: preclinical development. Neurosci Biobehav Rev 18:121–142 (10.1016/0149-7634(94)90042-6) / Neurosci Biobehav Rev by JM Witkin (1994)
  123. Wolpe PR, Gorton G, Serota R, Sanford B (1993) Predicting compliance of dual diagnosis inpatients with aftercare treatment. Hosp Commun Psychiatry 44:45–49 / Hosp Commun Psychiatry by PR Wolpe (1993)
  124. Woolverton WL, Virus RM (1989) The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food. Biochem Behav 32: 691–697 (10.1016/0091-3057(89)90019-1) / Biochem Behav by WL Woolverton (1989)
  125. Woolverton WL, Cervo L, Johanson CE (1984) Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacol Biochem Behav 21:737–741 (10.1016/S0091-3057(84)80012-X) / Pharmacol Biochem Behav by WL Woolverton (1984)
  126. Wysowski DK, Baum C (1989) Antipsychotic drug use in the United States, 1976–1985. Arch Gen Psychiatry 46:929–932 (10.1001/archpsyc.1989.01810100071013) / Arch Gen Psychiatry by DK Wysowski (1989)
  127. Yesavage J, Zarcone V (1983) History of drug abuse and dangerous behavior in inpatient schizophrenics. J Clin Psychiatry 44:259–261 / J Clin Psychiatry by J Yesavage (1983)
Dates
Type When
Created 19 years, 9 months ago (Nov. 15, 2005, 8:54 a.m.)
Deposited 2 years, 3 months ago (May 5, 2023, 8:38 a.m.)
Indexed 3 days, 18 hours ago (Aug. 28, 2025, 8:44 a.m.)
Issued 29 years, 11 months ago (Oct. 1, 1995)
Published 29 years, 11 months ago (Oct. 1, 1995)
Published Print 29 years, 11 months ago (Oct. 1, 1995)
Funders 0

None

@article{LeDuc_1995, title={Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence}, volume={121}, ISSN={1432-2072}, url={http://dx.doi.org/10.1007/bf02246489}, DOI={10.1007/bf02246489}, number={4}, journal={Psychopharmacology}, publisher={Springer Science and Business Media LLC}, author={LeDuc, P. A. and Mittleman, G.}, year={1995}, month=oct, pages={407–427} }